CALC
$0.58-0.16 (-21.68%)
Market ClosedAs of Mar 20, 8:00 PM UTC
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$0.58
Potential Upside
5%
Whystock Fair Value$0.61
Price
UndervaluedFair ValueOvervalued
Fundamentals
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an int...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.09M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
445.14%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.58
Recent News
CalciMedica’s stock drops 75% on acute kidney injury trial termination
The biopharma will now evaluate how it can safely progress Auxora’s development in AKI.
CalciMedica Insiders Added US$1.05m Of Stock To Their Holdings
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...